Compare HGV & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HGV | APGE |
|---|---|---|
| Founded | 1992 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.7B |
| IPO Year | 2017 | 2023 |
| Metric | HGV | APGE |
|---|---|---|
| Price | $44.59 | $134.49 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $52.13 | ★ $109.67 |
| AVG Volume (30 Days) | 1.1M | ★ 1.1M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 97.78 | N/A |
| EPS | ★ 0.95 | N/A |
| Revenue | ★ $5,047,000,000.00 | N/A |
| Revenue This Year | $25.30 | N/A |
| Revenue Next Year | $1.98 | N/A |
| P/E Ratio | $47.26 | ★ N/A |
| Revenue Growth | ★ 1.33 | N/A |
| 52 Week Low | $36.79 | $35.39 |
| 52 Week High | $55.40 | $134.88 |
| Indicator | HGV | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 40.52 | 76.68 |
| Support Level | $43.58 | $134.03 |
| Resistance Level | $49.22 | N/A |
| Average True Range (ATR) | 1.89 | 0.24 |
| MACD | -0.35 | -1.03 |
| Stochastic Oscillator | 18.66 | 54.12 |
Hilton Grand Vacations Inc is a timeshare company engaged in developing, marketing, selling, managing, and operating timeshare resorts and timeshare plans under the Hilton Grand Vacations brand. The company operates in two segments: Real estate sales and financing, and Resort operations and club management. The Real estate sales and financing segment generates revenue from VOI sales and consumer financing, including interest income from loans to members. The Resort operations and club management segment generates revenue from resort management services, club membership fees, and rental of available inventory. The majority of the company's revenue is earned through the Real estate sales and financing segment.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.